Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

IVD Medical Holding Limited
華檢醫療控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1931)

VOLUNTARY ANNOUNCEMENT

US Stablecoin License Application and Launch of IVDNewCo Exchange Ecosystem

This announcement is made by IVD Medical Holding Limited (the "**Company**", together with its subsidiaries, collectively the "**Group**") on a voluntary basis. This announcement intends to further update the progress of the strategic initiatives disclosed in the voluntary announcement (the "**Previous Announcement**") published by the Company dated 17 July 2025, and to provide shareholders and potential investors with information about the Group's business developments. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those used in the Previous Announcement.

I. STRATEGIC BACKGROUND AND CONTINUED PROGRESS

1. Strategic Review of the Previous Announcement

Reference is made to the Previous Announcement, in which the Company disclosed that the Group is actively constructing "NewCo + RWA" Web3 Exchange Ecosystem ("**IVDNewCo Exchange**"), with high-tech medical innovative drug assets (NewCo) as its core, and the associated plan to issue the stablecoin, "IVDDollar" (IVDD). The strategy aims to enhance the liquidity, financing efficiency and accessibility of global medical innovative drug assets by integrating Web3 technology. The Group has initiated compliant preparations for the purpose of applying for a US stablecoin license to support the global layout of the Ecosystem.

2. Milestone Events for Regulation of US Stablecoin

On 18 July 2025 (United States time), U.S. President Trump officially signed the Guiding and Establishing National Innovation for U.S. Stablecoins Act (the "**Genius Act**"). The Genius Act is the first national-level stablecoin regulatory framework in the United States, marking a significant milestone in the compliance process of digital assets. It is expected that the Genius Act will have far-reaching implications on global capital markets and the crypto industry. Hong Kong, as an international financial centre, has gazetted the Stablecoins Ordinance on 30 May 2025 (which will come into operation on 1 August 2025). The resonance of the Stablecoins Ordinance and the US policy is expected to have the effect of jointly promoting an accelerated development in the global stablecoin market.

II. MAJOR STEP FOR THE IMPLEMENTATION OF THE GROUP'S US STRATEGY

The Board is pleased to announce the following key developments of the Group in seizing the opportunity and in accelerating the Group's strategy as previously announced:

1. Establishment of a US Wholly-owned Subsidiary

A wholly-owned subsidiary of the Company, IVD GROUP INC. ("**US Subsidiary**") has been established in New York State, United States. The US Subsidiary will serve as the Group's core operational entity in the United States to promote the strategy of IVDNewCo Exchange.

2. Launch of the US Stablecoin License Application

The US Subsidiary has launched the work of a stablecoin license application to relevant US regulatory authorities (including but not limited to the SEC and CFTC). This substantive advancement of the Group's "US Stablecoin License Application Plan" set out in the Previous Announcement demonstrates the Group's execution capability and foresight in its global compliance layout.

3. Comprehensive Implementation of the IVDNewCo Exchange Ecosystem Plan

The US Subsidiary will simultaneously implement the construction of the IVDNewCo Exchange Ecosystem in the United States, including:

- Formation of a RWA (Real World Asset) tokenization platform based on medical innovative drug NewCo assets;
- Establishment a compliant financial infrastructure to support the issuance, trading and settlement of IVDD stablecoin;
- Promotion of a "token-equity linkage" mechanism of dual primary listing on Nasdaq (further information is included in the Previous Announcement), deepening the synergistic effects of the capital market.

III. STRATEGIC SYNERGY AND MARKET OPPORTUNITIES

1. First-mover Advantage and Timing Positioning

The Group disclosed its plan on US license application plan on 17 July 2025, the day before the signing of the Genius Act, becoming one of the very few listed companies in the Hong Kong stock market that has a clear layout for the compliant stablecoin ecosystem in the US. This substantive application rapidly initiated through the US Subsidiary may further consolidate its leading position in the "stablecoin concept sector of Hong Kong stock market".

2. Global Dual-hub Layout Taking Shape

The license application plan under the Hong Kong Stablecoins Ordinance (as disclosed in Previous Announcement), together with the establishment of the US Subsidiary, form the Group's "Hong Kong + US" dual financial hub compliance framework, providing cross-regional regulatory endorsement and liquidity support for the IVDNewCo Exchange Ecosystem.

3. Reshaping the Value Chain of Medical Innovative Drug Assets

Leveraging on the Group's commercialization network covering 1,674 Class III hospitals in China and its capabilities of acquiring global high-quality NewCo assets, the IVDNewCo Exchange Ecosystem will become the world's first compliant trading platform focusing on medical innovative drugs RWA, attracting two-way capital inflow from traditional medical capital and crypto-native funds.

IV. OUTLOOK AND INVESTOR REMINDER

The acceleration of the US strategy marks the entry of the Group's three-pronged strategy of "NewCo + RWA + Stablecoin" into the large-scale implementation phase. During the historical window period when the Genius Act reshapes the global stablecoin landscape, the Group, with a dual breakthrough of "stablecoin license application + exchange ecosystem implementation" through the US Subsidiary, wishes to participate in depth in the value distribution of the trillion-dollar compliant stablecoin market, and to create scarce growth premiums for shareholders.

The Group will strictly comply with US and Hong Kong regulatory requirements to promote its subsequent work. Announcement(s) will be made to disclose material developments in due course in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
IVD Medical Holding Limited
Lin Xianya
Executive Director

Hong Kong, 20 July 2025

As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Lin Xianya, Mr. Chan Siu Kei Ken and Mr. Law Kim Fai, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and six independent non-executive directors, namely, Dr. Zhong Renqian, Dr. Leung Ka Sing, Dr. Wong Sze Lok, Ms. Tai Yang, Mr. Xu Da and Mr. Zhang Jianlei.

This announcement contains forward-looking statements that reflect the Company's beliefs, plans or expectations about the future or future events. These statements are based on a number of assumptions, current estimates and projections, and are subject to risks, uncertainties and factors which may be beyond control. Actual outcomes may differ. These statements are not, and shall not be, relied upon as any assurance or representation as to the future or as a representation or warranty otherwise. Neither the Company nor its directors, officers, employees, agents, affiliates, advisers or representatives assume any responsibility to update these statements or to adapt them to future events or developments or to provide supplemental information in relation thereto or to correct any inaccuracies.

If there is any inconsistency between the Chinese and English versions of this announcement, the Chinese version shall prevail.